Drug Profile
IDX 184
Alternative Names: DX-184; IDX184Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Idenix Pharmaceuticals
- Class Antivirals; Nucleotides; Small molecules
- Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Hepatitis C
Most Recent Events
- 19 Feb 2015 Idenix completes phase II trial in chronic Hepatitis C in USA and Puerto rico (NCT01371604)
- 04 Feb 2013 Discontinued - Phase-I for Hepatitis C in USA (PO)
- 04 Feb 2013 Discontinued - Phase-II for Hepatitis C in Puerto Rico (PO)